about
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryThe homeobox gene Cdx1 belongs to the p53-p21(WAF)-Bcl-2 network in intestinal epithelial cellsIdentification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors.Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.Follicular lymphomas--a review of treatment modalities.Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial.BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells.Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA StudiesEORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.One-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic ScoreRole of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial.UV radiation exposure, skin type and lymphoid malignancies: results of a French case-control study.EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care.Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study.Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitationQuestionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.Chemotherapy treatment for older women with metastatic breast cancer: what is the evidence?Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature.Therapeutic strategies in elderly and very elderly patients.Referral of elderly cancer patients to specialists: action proposals for general practitioners.Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GNew drugs for follicular lymphoma in older adults.Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper.Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.Rational therapeutic choice for older patients with lymphoma.Immune checkpoint inhibitors and elderly people: A review.Targeted therapy and elderly people: A review.Treatment of the elderly patient with mantle cell lymphoma.Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy.Modeling individual and relative accuracy of screening tools in geriatric oncology.Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.[Comprehensive geriatric assessment (CGA) in elderly with cancer: For whom?].Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
P50
Q28088365-BF822033-70DB-4ED0-B1E3-A3889D2EC4EDQ28203367-13697D32-3C22-4538-9B40-0FA46A534D9AQ30164615-1C791531-04E3-4C47-81B1-7A68F59C65CBQ31150088-9F4F6551-F673-4A17-8C03-C1C44CE0DFCEQ33947861-D2A69CB8-89C6-48F2-856C-8F13D6988422Q34156097-AB4E0313-AF23-4A68-9F92-CDB8331C3D63Q34274135-10B8F8DC-5B37-49F6-8559-8E967FF16C55Q34485713-B5C47941-CDF7-4AAD-B269-3E0904CC3CF5Q34486392-13EA9D18-F1FA-4F34-B3DC-18A8266FF470Q35501693-3AE1BDF2-A1E2-4919-B22D-03F180CBCFB5Q35904127-D4B85B6F-2614-4679-B046-0287D16A8884Q35918084-2E332776-C6C3-462A-8F66-048637B125CBQ36210646-3FC7D00B-BB66-4A42-ABE8-2171C3EFC35AQ36571028-B679DF2A-6049-4CA9-A0ED-9A589F12D4CFQ36689459-9F739F8B-60D2-4974-8FE7-2E39EEFCD4E5Q36773610-CEEC5763-FA74-401B-BBE0-C1E31F3C2D39Q37309995-3ED6400C-E9E1-4D74-B066-3418F1616CB5Q37391931-E0A89AEF-C88A-4E81-8A8F-C4961F5C7472Q37604295-91C6DFD9-A230-4DB3-8135-EF2900F832EBQ37688550-81D11538-2D4B-47CB-AD06-FD5F4E3B5FF0Q37801220-E6EF888C-9813-4F77-9378-4559943B3417Q37877011-F8FCFF27-6C1A-4F58-B762-26ADD5203349Q37979768-4D07BED6-8F68-42F9-A65D-F9D85BD07BE1Q37992730-DF28C2E6-879D-4A9A-93B2-21B49B87FB23Q38005527-A880941E-1B96-4559-AF9D-8B37021C8FE5Q38056487-BE020DBB-3C0E-4051-9E80-5D00D407F961Q38205045-FAEB389B-791A-4D54-B994-6E6B17E48384Q38285791-C379AB77-E41D-41EA-93C1-492922EC008DQ38378318-F9054853-9E67-4D77-B0D0-8E4E8FECD248Q38662344-F1E02E09-2597-402D-9E19-7CF7761FB78BQ38688111-51ED1A6B-846A-4873-9C37-D3AF7404592CQ39010838-109572C7-0B1B-4514-8CFB-6347D0A62645Q39027813-8F58EA28-D246-4083-9177-FB4472AE0E04Q39027817-F88784B6-2A7E-4018-B5EF-D5C820CA440FQ39685534-91020A6A-BB09-4AA8-AC61-683C0D5EE00FQ39969990-A8E4BBBC-DB27-47B7-ABD5-E181C2592607Q40281171-1325CC97-4BD6-46EA-9F7D-279B76B494E4Q40616101-96A4ED1A-BBFE-43CE-A806-A25086351735Q40842477-404E515D-91E9-4F0A-81EF-2E629EDC3253Q40863791-8685BC58-A87C-4B0B-AFBB-6457CEF4C5A2
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-3244-7299
@en
name
P Soubeyran
@nl
Pierre-Louis Soubeyran
@en
Pierre-Louis Soubeyran
@es
type
label
P Soubeyran
@nl
Pierre-Louis Soubeyran
@en
Pierre-Louis Soubeyran
@es
altLabel
P Soubeyran
@en
prefLabel
P Soubeyran
@nl
Pierre-Louis Soubeyran
@en
Pierre-Louis Soubeyran
@es
P214
P106
P1153
54922947100
P21
P214
P31
P496
0000-0003-3244-7299
P734
P7859
viaf-85921070